Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma with poor long-term survival. This study assessed methotrexate (MTX) plus idarubicin (IDA) in treating patients of PCNSL comparing to MTX alone therapy. A total of 100 patients were retrospectively enrolled and subjected to MTX alone ( = 52) and MTX plus IDA ( = 48). The completed response (CR) rate in patients treated with MTX plus IDA was 62.50%, and overall response (OR) rate was 79.17%, which in MTX alone cohort were 42.31% and 63.46% respectively. Median progression-free survival (PFS) of patients treated with MTX plus IDA was significantly better than those treated with MTX alone (18.35 months .8.45months, = 0.000). The MTX plus IDA regimen exhibited a significantly better control of PCNSL. Further studies would be needed to confirm these results.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581143 | PMC |
| http://dx.doi.org/10.18632/oncotarget.15899 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.
J Neurooncol
May 2023
Department of Hematology, Huashan Hospital, Shanghai, China.
Purpose: High-dose methotrexate (HD-MTX)-based chemotherapy regimen is the first-line option for primary central nervous system lymphoma (PCNSL). This prospective cohort study aimed to evaluate the efficacy and adverse effects of HD-MTX plus idarubicin (IDA) in patients with newly diagnosed immunocompetent PCNSL.
Methods: We recruited newly diagnosed PCNSL patients from January 2017 to August 2020.
DNA-Based Electrodes and Computational Approaches on the Intercalation Study of Antitumoral Drugs.
Molecules
December 2021
Lafam-Laboratory for Pharmaceutical and Environmental Analysis, Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia 74605-170, Brazil.
The binding between anticancer drugs and double-stranded DNA (dsDNA) is a key issue to understand their mechanism of action, and many chemical methods have been explored on this task. Molecular docking techniques successfully predict the affinity of small molecules into the DNA binding sites. In turn, various DNA-targeted drugs are electroactive; in this regard, their electrochemical behavior may change according to the nature and strength of interaction with DNA.
View Article and Find Full Text PDFA case of acute diffuse large B cell lymphoma in an anti-human T-cell leukaemia virus type 1-positive rheumatoid arthritis patient treated with methotrexate, who died.
Mod Rheumatol Case Rep
July 2020
Division of Rheumatology, Kurume University Medical Center, Kurume, Japan.
A 70-year-old woman was hospitalised due to jaundice and fever. She was diagnosed with rheumatoid arthritis (RA) at 54 years of age. Treatment with methotrexate (MTX) was successful, and her RA was in remission.
View Article and Find Full Text PDFCombination of methotrexate and sulfasalazine is an efficacious option for axial spondyloarthritis in a resource-limited, real-world clinical setting: a prospective cohort study.
Clin Rheumatol
May 2021
Department of Clinical Immunology and Rheumatology, Christian Medical College & Hospital, Ida Scudder Road, Vellore, Tamil Nadu, 632004, India.
Objective: Evaluation of response to combination conventional synthetic DMARD (csDMARD) therapy with methotrexate (MTX) and sulfasalazine (SSZ) in active axial spondyloarthritis (axSpA) patients without peripheral arthritis (group 1) as compared to active axSpA with peripheral arthritis (group 2), who are economically constrained for biologicals.
Methods: A prospective, observational, single-centre, cohort study on 150 consecutive active axSpA patients who were already initiated on the above mentioned combination csDMARD therapy and satisfying the other pre-defined eligibility criteria, was conducted between July 2016 and July 2017 using ASAS20 response as primary outcome measure at 3 and 6 months post treatment.
Results: ASAS20 response at 3 months was achieved in 31/58 (53.
Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma.
Oncotarget
August 2017
Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma with poor long-term survival. This study assessed methotrexate (MTX) plus idarubicin (IDA) in treating patients of PCNSL comparing to MTX alone therapy. A total of 100 patients were retrospectively enrolled and subjected to MTX alone ( = 52) and MTX plus IDA ( = 48).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!